Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer

Author(s): Paul Brittain, S. Gail Eckhardt, Christopher H. Lieu

Journal Name: Current Cancer Therapy Reviews

Volume 10 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.

Keywords: Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 15 August, 2014
Page: [34 - 38]
Pages: 5
DOI: 10.2174/157339471001140815152055

Article Metrics

PDF: 36